drugset / Trial / NCT00168090

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

NCT00168090

Phase 4 Completed 30 enrolled CSL Behring
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.

Timeline

Start
2001-10
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Wilate Protein / enzyme biologic